Taking people in ItalyPhase 3
Tests combined diuretic medicines in people with chronic heart failure
Compares two diuretic treatment plans in adults with long-term heart failure.
Key facts
- Who runs it
- Centro Cardiologico Monzino S.p.A.
- Where
- Milan, ItalySee the site
- Trial code
- EU 2024-519565-21-01
- EudraCT 2022-003314-37
- U1111-1316-2467
- Registry title
- Effects of combined diuretic therapy on exercise capacity, alveolar-capillary diffusion and maintenance of euvolemia in chronic congestive heart failure, diuretic therapy compared with loop diuretics and potassium-sparing diuretics
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 44 people, planned
- Started
- 21 Sept 2023
- Expected to end
- 31 Jan 2027
- Type of study
- Interventional
- Record updated
- 18 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long-term heart failure who left hospital after a worsening of their heart failure. It compares two water-pill (diuretic) treatment plans.
- Age
- 18 to 80 years (the exclusion list also names under 18 or over 85 years).
- Sex
- Women and men can join.
- Disease stage
- Long-term (chronic) heart failure, with reduced or preserved pumping function. At least a second worsening (decompensation) needing hospital care in the past 12 months, and discharged after the latest hospital stay.
- Earlier treatment
- Taking a loop diuretic (water pill) at the dose of furosemide 40 mg (or equivalent) or higher at the time of hospital admission.
Main reasons for not taking part
- Severe narrowing of the aortic valve (severe aortic stenosis)
- Severe kidney failure (eGFR below 20 ml/min/1.73m2)
- Severe low blood sodium (severe hyponatremia)
- Heart failure medicines already optimized during the hospital stay
- Current pregnancy or breastfeeding in women who could have children
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- written informed consent signed
- Age: 18-80
- Patients with chronic heart failure (at reduced or preserved ejection fraction)
- Patients discharged after hospitalization for acute heart failure (at least second episode of decompensation in the past 12 months)
- Patients being treated with loop diuretics at the same or higher dosage of furosemide 40 mg (or equivalent) at the time of admission
Who cannot take part
- Medical therapy for heart failure optimized during hospitalization
- patients with severe renal failure (eGFR<20 ml/min/1.73m2 according to CockroftGault)
- age <18 years or >85 years
- patients with severe aortic stenosis
- patients with severe hyponatremia
- Documented current pregnancy and lactating status in women of childbearing potential
Where in Italy
- Centro Cardiologico Monzino S.p.A.Milan, ItalyTaking people
About the trial
What the trial wants to find out
To compare two different treatment strategies (control arm treated with loop diuretic and potassium sparing and experimental arm that will combine such therapy with acetazolamide and free-dose metolazone) in patients with chronic heart failure.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Effects of combined diuretic therapy on exercise capacity, alveolar-capillary diffusion and maintenance of euvolemia in chronic congestive heart failure, diuretic therapy compared with loop diuretics and potassium-sparing diuretics
- Plain-language title
- Tests combined diuretic medicines in people with chronic heart failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 18 December 2025